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Abstract: Decision-makers need to make choices to improve public health. Population-based 
newborn screening (NBS) is considered as one strategy to prevent adverse health outcomes 
and address rare disease patients’ needs. The aim of this study was to describe key 
characteristics of decisions for funding new NBS programmes in Europe. We analysed past 
decisions using a conceptual framework. It incorporates indicators that capture the steps of 
decision processes by health care payers. Based on an internet survey, we compared  
22 decisions for which answers among two respondents were validated for each 
observation. The frequencies of indicators were calculated to elicit key characteristics. All 
decisions resulted in positive, mostly unrestricted funding. Stakeholder participation was 
diverse focusing on information provision or voting. Often, decisions were not fully 
transparent. Assessment of NBS technologies concentrated on expert opinion, literature 
review and rough cost estimates. Most important appraisal criteria were effectiveness (i.e., 
health gain from testing for the children being screened), disease severity and availability 
of treatments. Some common and diverging key characteristics were identified. Although 
no evidence of explicit healthcare rationing was found, processes may be improved in 
respect of transparency and scientific rigour of assessment. 
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1. Introduction 
Population-based newborn screening (NBS) is considered as one public health strategy to prevent 
adverse health outcomes at infant age and improve the healthcare of rare disease patients [1,2]. Owing 
to the establishment of new technologies such as tandem mass spectrometry and identification of 
related gene mutations since the late 1990s and early 2000s, a variety of options have emerged to 
identify metabolic and genetic disorders at birth [3]. Given the public resources that can be spent for 
new screening programs are limited, choices need to be made about which of them should be 
conducted at the expense of public budgets. 
Currently, the outcomes of these choices differ across Europe because the screening practice is 
heterogeneous [4]. To better understand the reasons for this heterogeneity and to provide advice about 
how decisions can be improved, descriptive information is needed about how the decisions were made.  
A further investigation of this question reveals a number of challenges. For example, there are 
different criteria which could play a role in decisions about screening programs [5]. Methods of health 
technology assessment (HTA) have been developed for developing scientific evidence about whether 
or not a decision criterion is met. To date, the decision outcomes can hardly be explained by this 
scientific evidence because HTA still has a limited impact on decision practice [6]. Furthermore, 
health care funding in Europe is typically organized within a national health service or a statutory 
health insurance. Decisions to include new interventions into the scope of publicly funded services are 
therefore made in the context of complex institutional procedures which may also have an impact on 
the decisions but which are not easy to describe [7–9]. For example, it has been put forward that 
besides the reasonableness of the decision criteria, also characteristics of the decision processes such 
as participation and transparency are relevant for fair decisions about health care resource 
 allocation [10]. However, it is not straightforward to grade in a comparative manner to what extent 
different decision processes correspond with the fuzzy concept of “transparency”. The complexity of 
decision criteria and processes may additionally involve that perceptions about the characteristic 
values may differ so that it is difficult to obtain reliable information [11]. 
To obtain a comprehensive picture of decisions to fund new NBS programs, the objective of this study 
was to describe decision processes about new NBS programmes in Europe in a methodologically 
controlled manner. This involved a structured survey and an approach to validate the respondent’s answers. 
2. Methods  
Decisions that determine if and how a technology is included into the benefit basked of a health 
care payer can be analysed regarding several aspects, e.g., appraisal criteria, decision outcome, 
assessment methods or attributes of the decision process [12]. This study analysed these decisions 
from a process-oriented perspective. For this purpose, approaches have been developed to structure the 
characteristics of such decision processes at a national or regional level [7,8]. The conceptual 
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framework by Rogowski elaborates the stylized steps that a decision passes through from emergence 
into markets to technology diffusion in clinical use [8]. It has been derived from expert opinions and 
literature search. Whilst covering a manageable number of elements, it inherits three properties that are 
suitable for analysing NBS decisions at European level: (1) It takes a broad view, describing all items 
relevant in the decision process. (2) It is generic to enhance an international comparison of processes.  
(3) It is based on information which is comparatively easy to observe such that its elements can be analysed 
for the different countries. It was therefore used in our analysis and structures the steps as follows: 
 Scope of decision making: The process starts after the product has received marketing 
authorization or is known to have entered the scope of a payer. 
 Trigger: As different decision bodies may coexist at national and regional level, the process of 
the responsible body needs to be triggered. 
 Participation: There are different stakeholders who may be involved in the decision, e.g., 
manufacturers, service providers or patients. 
 Publication: During the different steps, the decision-maker can disclose information about the 
process or its outcome. 
 Assessment: The decision-maker applies some method of assessing the technology, e.g., by 
systematic literature review or expert opinion. 
 Appraisal: A decision about whether to cover a technology is made based on an appraisal of 
certain criteria, e.g., a product’s effectiveness or cost-effectiveness. 
 Reimbursement: In the case of a positive decision, a mechanism for reimbursement (i.e., the 
level and mechanism of funding) has to be determined. 
 Management: Besides funding the use of a technology, the payer may exert influence on 
service provision. 
For this conceptual framework, a corresponding set of indicators for each step (see Table A1.for a 
description of the operationalization) has been developed [9]. The indicators were obtained from six 
case studies from the domain of cancer prevention, complemented by expert discussion. This allows 
structured comparison between decisions using pre-defined items in each step. 
The conceptual framework and the set of indicators have been used for a survey of coverage 
decisions on NBS made between 2005 and 2009 of the EU 7th framework project HIScreenDiag  
(Grant No. 223533) [13]. Experts affiliated either to NBS providers or third party payers were 
approached via a scientific society (International Society of Neonatal Screening). They completed  
an internet survey on past decisions of NBS in their country/region they were familiar with by direct 
involvement or as an outside observer. The survey was conducted between August and December 
2009. Respondents were asked for decisions made in the last five years to reduce recall bias.  
Forty-three respondents from 21 countries completed the questionnaire (response rate 70%). 
Respondents were contacted via an internet survey which included questions that covered the 
indicators of the structured scheme. 
This study followed the principles of Good Scientific Practice issued by the German Research 
Foundation [14]. This includes the application of methods following the state of the art which was 
oriented at a textbook by Schnell et al.; for example, all respondents were offered confidentiality [11]. 
No approval by the responsible medical ethics board in addition to these standards was obtained 
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because the survey addressed technical experts and decision makers with regard to reimbursement 
decisions. The study was not medical but socio-economic health services research. Neither patient nor 
any identifiable patient data was analysed. This kind of research was thus considered out of the scope 
of the World Medical Association (WMA) Declaration of Helsinki which addresses “medical research 
involving human subjects, including research on identifiable human material and data” [15].  
We used the data set to elicit the key characteristics by the steps of decision-making. Plausibility 
and implications of the findings were discussed with the members of the HIScreenDiag project 
consortium to conclude in key characteristics of NBS decision-making for each step. 
The survey included NBS conditions that have been considered for coverage for which a testing 
technology is available. We limited the scope of the study to blood spot screening. The decision could 
be made for an NBS programme that includes several conditions screened in one assay  
(e.g., introduction of MS/MS that covers several targets) or, expansion of an existing NBS programme 
by a condition, potentially involving the introduction of a new technology. Each target was considered 
as one decision for cost coverage. We disregarded all decisions that determine the exact technical 
implementation of an assay as these have been described previously [16]. 
A decision object was defined by screening method, tested condition, patient group and further 
specifics of the testing strategy. It could result in full, partial or no financial coverage. The study 
focused on screening for medium-chain acyl-CoA dehydrogenase deficiency (MCADD), cystic 
fibrosis (CF) and congenital adrenal hyperplasia (CAH). These conditions were identified in 
exploratory analyses as frequent decision objects [16]. If none of the conditions were identified, the 
research design was capable to include other case studies if respondents could not provide information 
about the above mentioned decisions. 
The International Society for Neonatal Screening served as a platform to make contact with two 
experts per each EU member state and Switzerland involved in decision-making. From a total of  
55 decisions, the 22 decisions from 11 countries that had been cross-validated by two experts were 
kept. Table 1 displays the included decisions by country which cover about 50% of the EU population. 
A first comparison of answers for same decisions showed that the inter-rater reliability was low. To 
ensure validity, data were compared for the decisions where two respondents provided answers. If 
deviations occurred, a Delphi procedure was applied. Here, we compared the answers of the two 
experts question by question. In case of deviations, we sent the diverging answers to the two experts 
again without disclosure of the other respondent’s name. The experts were asked for the reasons why 
their answers deviated and what they believed the correct answer was. The procedure was stopped 
when the percentage of conflicts remained in less than 5% of answers. Then, statements from the 
expert with the closest relation to the decision were considered, e.g. statements from payers were 
preferred to service providers. 
For each indicator, we calculated the frequencies of categories. Data evaluation was performed with 
SAS Version 9.2 (SAS Institute, Cary, NC, USA). For the relevance of appraisal aspects, we considered 
the answers from both respondents. 
  
Int. J. Environ. Res. Public Health 2014, 11 5407 
 
Table 1. Coverage decisions on newborn screening (NBS) programmes in Europe considered. 
Country 
(by population size) 
Metabolic / genetic disorders considered 
in coverage decision 
Germany MCADD, CAH 
France CF 
England MCADD, Hb SS, CF 
Romania PKU, CH a 
Netherlands MCADD, Hb SS 
Czech Republic CAH, CF 
Hungary MCADD, MSUD, GALT 
Switzerland MCADD 
Denmark MCADD, CAH 
Slovenia b MCADD, CAH 
Belgium: Region of Flanders MCADD, BIO 
a Expansion of number of newborns screened; b Selective screening; Abbreviations: BIO, biotinidase deficiency; 
CAH, congenital adrenal hyperplasia; CF, cystic fibrosis; CH, congenital hypothyroidism; GALT, classical 
galactosaemia (galactose-1-phosphate uridyltransferase deficiency); Hb SS, sickle cell disorders; MCADD, 
medium-chain acyl-CoA dehydrogenase deficiency; MSUD, maple syrup urine disease; PKU, phenylketonuria. 
3. Results and Discussion 
For each step of the framework, we identified several characteristics which we summarized in  
Table 2. Frequencies of indicators for the steps scope of decision-making, trigger, publication, 
assessment, appraisal, reimbursement and management are displayed in Table 3. Results of the step 
participation are provided in Table 4. An overview by country is provided in Table A2. 
3.1. Scope of Decision-Making 
Decisions may depend on their scope, i.e., whether they are made at individual, service provider, 
regional or national level. All decisions about NBS technologies were made by tax funded sources or 
the respective statutory health insurance. Except for the Flanders region in Belgium, decisions were 
made at national level (the UK National Screening Committee decision for England was considered as 
a national decision). 
3.2. Trigger 
Not all new technologies are subject to explicit coverage decisions. It is therefore important to 
consider how a decision process was triggered. Almost three fourth of decision processes were 
reported to be started after application of explicit criteria.  
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Table 2. Characteristics of coverage decision processes of NBS programmes in Europe, according to 22 decisions obtained from expert survey. 
Step of decision process Characteristics 
Scope of decision-making 
Often not explicitly addressed by “typical” decision-making committees for financial coverage; 
In many countries, decisions were made at macro (i.e., national) level. 
Trigger Start of decision processes predominantly after explicit specification of criteria. 
Participation 
Diverse participation of stakeholders; 
Service providers (laboratories) took high influence; 
Compared to pharmaceuticals, industry less involved; 
Stakeholders often involved in voting. 
Publication 
Information on decisions can hardly be validated via web- or document-search; 
Decision outcome not reported in about 10% of decisions; 
Stakeholder comments, HTA report, rationale for assessment question reported in less than 25% of decisions; 
Additionally some related information, but never full documentation of the process. 
Assessment 
Use of scientific evidence on effectiveness in 86% of decisions, but in 9% based on expert opinion only; 
Systematic review frequently indicated but often no possibility for validation; 
seven decisions with HTA; 
Assessment of cost predominantly based on cost-estimate. 
Appraisal 
High diversity of appraisal aspects; 
Health gain from testing for the children being screened, severity and availability of treatment for disease most relevant; 
Economic aspects less relevant; 
Lobbying activities had minor to no relevance. 
Reimbursement 
Predominantly positive, unrestricted funding; 
Different types of reimbursement: predominantly per test, insured, year. 
Management 
In at least one fifth of decisions no further reporting required to payer; 
Predominantly specific information about screening required. 
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Table 3. Overview of indicators from internet survey of decisions on NBS in European 
countries (n = 22). 
Decision step Indicator Category n % (rounded) 
Scope of 
decision-making 
Type of third party 
payment 
Tax funded 11 50% 
Statutory health insurance 11 50% 
Trigger Start of decision process 
Explicit specification of criteria for trigger 16 73% 
Ad-hoc selection 6 27% 
Publication 
Reporting a 
Decision outcome 20 91% 
Decision rationale 7 32% 
Health technology assessment report 7 32% 
Attendance at or minutes of appraisal meeting 6 27% 
Stakeholder comments 3 14% 
Rationale for assessment question from scoping 2 9% 
No information available 2 9% 
Other 0 0% 
Transparency 
Missing 11 50% 
Publication of decision and some supporting 
documents only 
2 9% 
Decision and some supporting information 8 36% 
Selected relevant documentation 1 5% 
All process relevant documents 0 0% 




Expert opinion 20 91% 
Systematic literature review 19 86% 
Other type of assessment 10 45% 
Quantitative meta-analysis of studies 2 9% 
No assessment of effectiveness 1 5% 
Assessment of 
costs/cost-effectiveness 
No assessment of costs 2 9% 
Cost estimate 16 72% 
Cost-effectiveness analyses 4 18% 
Appraisal 
Effectiveness (health 
gain from testing) 
Not relevant 2 9% 
Relevant 4 18% 
Strongly relevant 16 73% 
Severity of the disease 
Not relevant 4 16% 
Relevant 7 32% 
Strongly relevant 11 52% 
Availability of 
treatment for disease 
Not relevant 4 16% 
Relevant 9 41% 
Strongly relevant 9 43% 
Quality of evidence 
Not relevant 6 25% 
Relevant 11 52% 
Strongly relevant 5 23% 
Expected costs 
Not relevant 10 45% 
Relevant 7 34% 
Strongly relevant 4 20% 
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Table 3. Cont. 
Decision step Indicator Category n % (rounded) 
Appraisal 
Cost-effectiveness 
Not relevant 11 50% 
Relevant 7 30% 
Strongly relevant 4 20% 
Budget impact 
Not relevant 9 39% 
Relevant 11 52% 
Strongly relevant 2 9% 
Effect on equitable 
access to health care 
Not relevant 13 59% 
Relevant 8 36% 
Strongly relevant 1 5% 
Effectiveness (other 
benefit of knowledge 
from testing) 
Not relevant 15 70% 
Relevant 6 25% 
Strongly relevant 1 5% 
Lobbying by service 
provider(s) 
Not relevant 13 57% 
Relevant 9 41% 
Strongly relevant 0 2% 
Lobbying activities by 
patients/patient 
representatives 
Not relevant 11 50% 
Relevant 11 48% 
Strongly relevant 0 2% 
Scientific interest in 
gathering further 
evidence 
Not relevant 18 80% 
Relevant 4 20% 
Strongly relevant 0 0% 
Lobbying activities by 
industry 
Not relevant 22 98% 
Relevant 0 2% 
Strongly relevant 0 0% 
Lobbying by 
government 
Not relevant 22 100% 
Relevant 0 0% 
Strongly relevant 0 0% 
Third payer’s concern 
for cost containment 
Not relevant 22 100% 
Relevant 0 0% 
Strongly relevant 0 0% 
Reimbursement 
Decision outcome 
Full cost coverage 18 82% 
Partial cost coverage 4 18% 
No coverage 0 0% 
Type of reimbursement 
(after decision) a 
Per test 15 68% 
Per year 6 27% 
Per covered individual 3 14% 
Per diagnosis related group based case 2 9% 
Other 0 0% 
Co-payment from insured 0 0% 
Mix of types of 
reimbursement 
After decision 6 27% 
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Table 3. Cont. 
Decision step Indicator Category n % (rounded) 
Reimbursement 
Type of reimbursement 
(before decision) a 
Other (including no reimbursement) 7 32% 
Per test 6 27% 
Co-payment from insured 4 18% 
Per year 3 14% 
Per diagnosis related group based case 2 9% 
Per covered individual 1 5% 
Management 
Information provision 
of service provider 
At least number of reimbursed services 6 27% 
At least specific information about services 13 59% 
At least pre-authorization of services 3 14% 
Note: a More than one was answer possible. 
Table 4. Stakeholder participation (n = 22 coverage decisions). 
Stakeholder Type of 
involvement n (%) a 
Service 
provider(s) 
Payer Patients Government Industry Other 
No involvement 1 (5%) 4 (18%) 7 (32%) 3 (14%) 20 (91%) 17 (77%) 
Information provision b 17 (77%) 6 (27%) 14 (64%) 5 (23%) 0 (0%) 8 (36%) 
Appeal b 1 (5%) 0 (0%) 1 (5%) 0 (0%) 0 (0%) 3 (14%) 
Voting b 2 (9%) 12 (55%) 1 (5%) 9 (41%) 1 (5%) 0 (0%) 
Notes: a rounded; b More than one answer was possible. 
Examples were availability of new research evidence (England), revision of screening criteria (The 
Netherlands) or, the right of proposal by expert groups (France). However, criteria did not become 
evident for most decisions although respondents were able to make specifications in the questionnaire. 
3.3. Participation 
Various types of stakeholders participated in decision-making. Table 4 provides an overview of 
participation by stakeholders and their type of involvement. Involvement by service providers, the 
payer and government was most frequent. Neither government nor payers were involved in Romania. 
Besides public authorities, service providers were strongly involved. In a number of countries these are 
concentrated to few national centres, e.g., in Germany, Denmark or Hungary [4]. Compared to 
pharmaceuticals where manufacturers often need to submit applications, respondents indicated that 
industry was explicitly involved only in Switzerland and France [17]. In the Danish decisions and in 
Romania for expansion of screening coverage for phenylketonuria (PKU), neither involvement by 
industry nor service providers was reported. Involvement by patients cannot be disregarded as 
participation was reported in 68% of decisions.  
Stakeholder involvement concentrated on providing information relevant for the decision and 
voting on the final outcome. Information was mainly prepared by service providers and patients. The 
payer and government were those who were involved in voting most frequently. 
  




Transparency is frequently demanded to ensure fair decision-making. For the step “publication”, this 
was described by the types of documents provided and the degree of transparency which we derived from 
the type of information. Publication of the decision outcome, rationale, a related HTA report and minutes 
from the appraisal meeting were reported most frequently. In the decisions in the Czech Republic, 
information on the decision outcome was not provided publicly. Stakeholder comments and the rationale 
for the assessment question from scoping were reported in less than 20% of decisions. An HTA report was 
provided in Denmark, The Netherlands and England. There was no decision with complete documentation 
or at least including process relevant documents. Validation of reported documentation was difficult, 
because we frequently could not obtain related information on websites. No information was provided in 
the decisions made in Slovenia. In 50% of decisions only one type of documentation was published. 
3.5. Assessment 
The principles of evidence-based healthcare require that decisions are based on best available evidence. 
This was considered in the step of ‘assessment’. The survey investigated standard elements of technology 
assessment in terms of effectiveness and cost-effectiveness. According to the respondents, effectiveness 
was predominantly assessed by a systematic literature review. However, we could not validate this for 
every decision. From 19 decision processes reporting an own review, information on the search strategy 
was obtained for ten cases. In other six cases, we could not identify a systematic review. Despite of recent 
economic evaluations on NBS, we found that the assessment of costs/cost-effectiveness was based on  
a cost estimate rather than a full economic evaluation in 73% of decisions [18]. Cost-effectiveness analyses 
have been conducted in 18% of decisions. In Slovenia, costs were not assessed. 
3.6. Appraisal 
Ultimately, the decision maker’s choices in favor or agains funding a technology involve value 
judgments. According to Daniels and Sabin, the principles of fair allocation of scarce health care resources 
require that decision makers only apply those aspects in decision making for which all fair-minded parties 
agree that they are relevant for appropriate care under resource constraints [19]. Appraisal criteria which 
are frequently cited in the literature contain concerns about the intervention’s effectiveness and  
cost-effectiveness, severity of disease or equity considerations [20]. The appraisal criteria applied in 
this survey were based on a previous review and qualitative case study [9]. As an indicator or criteria 
which may meet these criteria to a lower extent, the survey additionally included particular 
interests/lobbying activities of stakeholders. 
By far, effectiveness in terms of health gain from testing (73% of decisions), disease severity 
(52%), and the availability of a treatment (43%) were most frequently rated as strongly relevant. 
Aspects related to economic criteria were considered in fewer decisions (cost-effectiveness, expected 
costs (each 20%) and budget impact (9%)). Although stakeholders participated in all processes to some 
extent, stakeholder interests were reported to have minor influence during appraisal. Amongst these, 
patients’ interests appeared most relevant. They were strongly relevant in the decision on medium-chain 
Int. J. Environ. Res. Public Health 2014, 11 5413 
 
 
acyl-CoA dehydrogenase deficiency (MCADD) screening in England. Service provider interests 
played a role in the decision on galactosaemia screening in Hungary. 
3.7. Reimbursement 
Positive decisions do not inevitably mean that a technology is fully funded. Instead, different 
reimbursement payment schemes may co-exist within one health care system for different types of 
technologies, e.g., capitation-based reimbursement, fee for service. These may deviate from the actual 
cost of a medical service. Four decisions resulted in partial coverage (i.e., only a part of the costs of 
screening are funded by the payer), all other programmes were granted full coverage. None of the 
technologies were excluded from funding. At least 70% of technologies have received funding to some 
extent before the final decision was made. For example, pilot studies were supported in certain regions 
or, the screening was provided from special budgets. For 18% of technologies services could be 
obtained through co-payments before the decision. After the decisions, reimbursement was 
predominantly provided per test or as a fixed budget while capitation-based payment or reimbursement 
within a DRG-catalogue had minor relevance. 
3.8. Management 
To complement the reimbursement regime, payers may exert influence on service provision by 
other means, e.g. by implementing requirements to monitor service provision in more detail than just 
counting the number of services. For about 60% of decisions, the payer has introduced requirements to 
report programme information. For example, outcomes of the NBS programme in Germany are 
disseminated biannually [21]. Pre-authorization was only required from the payer before the test may 
be conducted in the Flanders region (Belgium) and for expansion of PKU screening in Romania. 
4. Discussion  
4.1. Interpretation of Results 
For the 22 decision processes on NBS programmes in Europe, we identify a number of common 
and diverging characteristics. Decisions were typically made at national healthcare system level. 
Processes were rather intransparent in terms of the documents provided. Effectiveness of the screening 
strategies was predominantly assessed by expert opinion and systematic reviews. Of note, the use and 
relevance of systematic reviews may be over-estimated from our results as we could not reassure the 
presence of a systematic review in six of 20 decisions.  
The lower evidence standards for effectiveness and cost-effectiveness compared with 
pharmaceuticals (e.g., randomized controlled trials) may be due to the fact that high levels of evidence 
are typically difficult to meet for NBS technologies. The main reasons are that many disorders account 
as orphan diseases, the natural history of the diseases is not well characterized, an effective treatment 
may not be available or, treatment effects are highly uncertain [22]. For example, for CF, the evidence 
on effectiveness is ambiguous [5]. 
Economic criteria that consider a technology’s cost, cost-effectiveness or budget impact seemed to 
have minor relevance. For many programmes, this may be due because of two reasons [23]: (1) The 
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direct costs of additional screening tests are relatively low. (2) Considerable uncertainty is often 
involved in the effects that are generated by the available treatment options after screening such that 
economic considerations are overruled. Thus, it seems that not only have economic criteria played 
little role but also the evidence of effectiveness has been interpreted more positively than  
a conservative application of the principles of evidence-based medicine would imply. Moreover, 
despite discussions about scarce healthcare resources, our data do not reveal examples of healthcare 
rationing: although our survey design allowed for negative decision outcomes, all funding decisions 
were positive and economic considerations were reported to be of minor relevance in appraisal. 
The decision processes were less homogenous in the steps of participation, reimbursement and the 
relevance of appraisal criteria. These steps appear to especially reflect the diversity of healthcare 
systems in terms of the funding arrangements within which NBS is provided, the establishment of 
stakeholder roles and the diverging value judgements of policy-makers.  
The industry was hardly involved. One explanation for this could be that in the eight decisions 
made on MCADD, the treatment does not involve costly pharmaceuticals, but mainly consists of 
avoiding staying without food for a long time. On the contrary, patients seemed to have sufficient 
possibilities to at least provide information.  
4.2. Limitations 
The study is faced with a number of limitations which also reveal difficulties with characterizing 
the apparently simple topic of funding decisions in a comparative manner. Naturally, one would 
assume that decisions are made when the question arises whether a service should be implemented. 
Given that all assessed decisions were positive, formal decisions may rather have been made for 
confirmatory purposes after a medical or political decision in favour of screening had already been 
made, e.g., by funding a pilot stage of the programme. The assessment of the process step “trigger” 
appears to capture this to a very limited extent. Future studies should explore the shape and role of the 
process of technology implementation before a formal coverage decision [21]. Negative “pre-decisions” 
in the face of a positive funding decision may be identified for example by comparing conditions 
included in pilot tests with those in the final screening panel. For example, after a pilot phase in the 
German state of Bavaria between 1999 and 2004, not all conditions were recommended for universal 
screening under statutory health insurance [24]. 
Our results are limited by the small number of decisions that were included. This restricted statistical 
analysis to counting frequencies instead of multivariate analyses. A larger sample size and multivariate 
approaches would be needed to control for clustering effects by country or disease and to determine the 
impact of the steps of decision-making on the criteria used in appraisal or on decision outcomes. First 
evidence on the influences of the process steps has been provided for a sample of coverage decisions on 
health technologies not being restricted to a certain disease area. It indicated that rigorous assessment and 
stakeholder participation promoted reasonable decision-making whilst transparency did not have an 
influence [25]. Also, decision outcomes of coverage decisions appeared to be influenced mostly by the 
use of evidence rather than the degree of transparency or participation [26].  
However, the small number of included was also because only information validated during  
a Delphi process was included which appeared to be an important methodological approach to obtain 
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reliable results. Before the Delphi procedure, the inter-rater reliability for the rather simple, structured 
questions was very low. An explanation for this could be the poor documentation so that recalling the 
actual course of decision processes was difficult. We only included data which were validated by two 
respondents as the Delphi method allowed increasing the concordance between respondents by 50% to 
about 95%. However, this method was very lengthy.  
The results do not reflect decision-making of member states in the South of Europe (e.g., Spain, Italy) 
as no answers were obtained from these regions that have been evaluated by two respondents. Finally, 
we have to note that only decisions made between 2005 and 2009 were included. After this point in time, 
decisions on NBS were made in a number of countries, for example for MCADD in France [27]. 
4.3. Implications for Further Research 
In relation to existing literature on NBS policies, this survey is among the first that emphasizes the 
process of funding decisions. Previous studies have dealt with screening algorithms and technical 
description of the programmes [4,16,28,29]. Further research presents case studies of selected 
countries or disorders [30–33]. Other studies focus on the definition of appraisal criteria from which 
our approach departed [5,34,35]. While most studies refer to the Wilson and Jungner criteria which are 
dedicated to appraisal of screening programmes [3,5], we use a set of general clinical, economic and 
other ethical criteria that are comparable across different types of intervention or healthcare systems. 
Even if this study used a validated framework for describing the decision processes and the criteria 
used [9], the description and analysis of health care funding decisions remains a young area of health 
services research. Further work is necessary to better describe and understand these choices which 
determine the health services available to patients. 
Particular evaluation frameworks for genetic tests have been developed such as the ACCE framework 
that provides a tool to evaluate analytic validity, clinical validity, clinical utility and ethical, legal and 
social issues for genetic testing have been developed [23,36,37]. However, as the technological options 
available to payers rise, there is a tendency that coverage is evaluated and determined by a single body 
that deals with the majority of health services, e.g., in France [38]. In parallel, economic considerations 
appear to gain in importance such that NBS will likely need to show cost-effectiveness which goes 
beyond the scope of the established criteria for screening technologies [39]. Besides further work 
regarding the positive description and analysis of decisions about health care funding, also further 
work about relevant evaluation frameworks is needed to ensure that the evaluation frameworks 
appropriately account for fairness concerns. Also, the appropriate balance between generic frameworks 
to facilitate consistent decisions across all areas of health care and condition-specific frameworks to 
facilitate sensitivity for aspects particularly relevant for clinical areas such as NBS are needed. 
There are attempts to harmonize decision processes for new NBS programs across Europe [40,41]. 
Also in the United States, national evidence based guidance provided in the core panel by the 
American College of Medical Genetics (ACMG) led to harmonization of screening panels at state level 
and reducing inequity [42]. This study illustrates potential areas of improvement which might benefit 
from standardization on an EU level, for example regarding the limited transparency or the fact that 
decisions were not always based on evidence a proponent of evidence-based medicine might expect. 
However, it also illustrates that currently, much remains to be learnt about how decisions to fund new 
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NBS programs are made today. Further research about the status quo thus be an important starting 
point to ensure that new decision frameworks do indeed build upon the best practices rather than 
repeating regional or national mistakes on the level of the EU or the US. 
5. Conclusions  
This study elicits key characteristics of cost coverage decision-making on expanded population-based 
NBS programmes across Europe by the steps of decision processes. Despite variations, most payers of 
public healthcare systems have defined mechanisms to assess and appraise NBS. Characteristics show 
that most processes allow diverse stakeholder participation and appraise technologies most frequently 
regarding their effectiveness, the disease severity and treatment availability. We identify potential for 
improvement in transparency of decision-making and the use of evidence regarding cost-effectiveness. 
Despite discussions about scarce healthcare resources, explicit healthcare rationing was not identified.  
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Appendix  
Table A1. Operationalization of steps of conceptual framework. 
Decision Step Operationalisation Indicator(s) 
Scope of decision-
making 
Classification of type of health 
care system funding. 
Type of third party payment 
- Tax funded 
- Statutory health insurance 
Trigger 
Information whether decision 
process was started by definition 
of explicit criteria for selection of 
technology or, technology was 
selected ad-hoc. 
Start of decision process 
- Ad-hoc selection 
- Explicit specification of criteria for trigger 
Participation 
Number and types of different 
stakeholders being formally 
involved and their involvement. 
Types of stakeholders involved: 
- Service provider(s) 
- Payer 
- Government 
- HTA group or agency 
- Patients/patient representatives 
- Industry 
- Academia 
- Other stakeholder(s) 
Level of involvement of formally participating 
stakeholders: 




Number and types of different 
documents that have been 
published during or after the 
decision process. 
Types of documentation accessible to public 
during/after decision process 
- Attendance at or minutes of appraisal meeting 
- Decision rationale 
- Decision outcome 
- Stakeholder comments 
- Rationale for assessment question from scoping
- No information available 
- Other 
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Table A1. Cont. 
Decision Step Operationalisation Indicator(s) 
Assessment 
Methods that were used for 
assessment of effectiveness 
and costs/cost-effectiveness. 
Assessment of effectiveness: 
- No assessment of effectiveness 
- Expert opinion 
- (Systematic) literature review 
- Quantitative meta-analysis of studies 
Assessment of cost-effectiveness: 
- No assessment of cost-effectiveness 
- Cost estimate 
- Cost-effectiveness analyses 
Appraisal 
Aspects that were considered 
relevant or strongly relevant 
for the decision outcome 
Aspects relevant for outcome of decision 
Effectiveness (other benefit of knowledge from testing) 
Severity of the disease 
Availability of treatment for disease 




Effect on equitable access to health care 
Effectiveness (other benefit, e.g., knowledge of test result)
Lobbying by service provider(s) 
Lobbying by patients/patient representatives 
Scientific interest to gather further evidence 
Lobbying by industry 
Lobbying by government 
Third payer’s concern for cost containment 
Reimbursement 
Different mechanisms of 
reimbursement may have been 
before and after the decision. 
Decision outcome 
- Full cost coverage 
- Partial cost coverage 
- No cost coverage 
Type of reimbursement (before decision) 
- Per test 
- Per year 
- Per covered individual 
- Per diagnosis related group based case 
- Other 
- Co-payment from insured 
Type of reimbursement (after decision) 
- Per test 
- Per year 
- Per covered individual 
- Per diagnosis related group based case 
- Other 
- Co-payment from insured 
Management 
After the decision, the payer 
may have requested regulations 
for implementation of the 
technology 
Information provision of service provider 
- Number of reimbursed services 
- Specific information about services 
- Pre-authorization of services 
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Table A2. Results by country. 
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Abbreviations: CAH: Congenital Adrenal Hyperplasia; CE: cost-effectiveness; CF: cystic fibrosis; CH: Congenital hypothyroidism; DRG: Diagnosis-related group; HTA: 
Health Technology Assessment; MCADD: Medium-chain acyl-CoA dehydrogenase deficiency; NHS: national health service; SHI: statutory health insurance; 
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